Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.94 per share which beat the analyst consensus estimate of $1.61 by 20.5 percent. This is a 177.14 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $814.500 million which beat the analyst consensus estimate of $763.112 million by 6.73 percent. This is a 42.25 percent increase over sales of $572.600 million the same period last year.